PPAR Gamma Agonist Leriglitazone Recovers Alterations Due to Pank2-Deficiency in hiPS-Derived Astrocytes

• Ngā kaituhi matua: Paolo Santambrogio (Author), Anna Cozzi (Author), Ivano Di Meo (Author), Chiara Cavestro (Author), Cristina Vergara (Author), Laura Rodríguez-Pascau (Author), Marc Martinell (Author), Pilar Pizcueta (Author), Valeria Tiranti (Author), Sonia Levi (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2023-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

The novel brain-penetrant peroxisome proliferator-activated receptor gamma agonist leriglitazone, previously validated for other rare neurodegenerative diseases, is a small molecule that acts as a regulator of mitochondrial function and exerts neuroprotective, anti-oxidative and anti-inflammatory ef...